Future Directions to Establish Lipoprotein(a) as a Treatment for Atherosclerotic Cardiovascular Disease

被引：0
作者：
Evan A. Stein
Frederick Raal
机构：
[1] Metabolic and Atherosclerosis Research Center,Carbohydrate & Lipid Metabolism Research Unit, Faculty of Health Sciences
[2] University of Witwatersrand,undefined
来源：
Cardiovascular Drugs and Therapy | 2016年 / 30卷
关键词：
Lipoprotein(a); PCSK9 inhibitors; Niacin; Statins; CETP inhibitors;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
In both epidemiologic and genetic studies, increased levels of Lp(a) have been associated with increased risk for cardiovascular diseases as well as aortic stenosis. However, until recently, it has been difficult to lower levels of Lp(a). Diet and lifestyle have little effect on plasma levels of Lp(a) which are mainly genetically determined. Emerging therapeutic agents which have recently become available, or which are undergoing clinical trials, can significantly lower Lp(a) levels. Studies with these agents will hopefully be able to provide more direct information whether reductions in Lp(a) will reduce CVD events independently of reduction in LDL-cholesterol levels.
引用
收藏
页码：101 / 108
页数：7
相关论文
共 255 条
  • [31] Seishima M(2011)Comparison of the effects of simvastatin vs. rosuvastatin vs. simvastatin/ezetimibe on parameters of insulin resistance Int J Clin Pract 65 1141-8
  • [32] Makino K(2011)Farsenoid X receptor represses hepatic human apo(a) gene expression J Clin Invest 121 3724-34
  • [33] Noma A(1985)Brewer HBJr, levels of lipoprotein (a) Lp(a) decline with neomycin and niacin treatment Atherosclerosis 57 293-301
  • [34] Kawade M(1989)Pronounced lowering of levels of lipoprotein (a) Lp(a) in hyperlipidemic subjects treated with nicotinic acid J Intern Med 226 271-276
  • [35] Mbewu AD(1996)Efficacy and tolerability of low dose simvastatin and niacin, alone and in combination, in patients with combined hyperlipidemia: a prospective trial J Cardiovasc Pharmacol Ther 1 107-116
  • [36] Durrington PN(2002)Sheehan JP; Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 1568-76
  • [37] Bulleid S(1998)Brody. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study Am J Cardiol 82 74U-81U
  • [38] Gidding SS(1998)Clinical trial experience with extended-release niacin (Niaspan): dose-escalation study Am J Cardiol 82 35U-38U
  • [39] Stone NJ(2001)Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects Braz J Med Biol Res 34 177-182
  • [40] Bookstein LC(2012)Effects of prescription niacin and omega-3 fatty acids on lipids and vascular function in metabolic syndrome: a randomized controlled trial[S] J Lipid Res 53 2429-2435
12345678910